<SEC-DOCUMENT>0000950170-24-093307.txt : 20240808
<SEC-HEADER>0000950170-24-093307.hdr.sgml : 20240808
<ACCEPTANCE-DATETIME>20240808071007
ACCESSION NUMBER:		0000950170-24-093307
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20240808
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240808
DATE AS OF CHANGE:		20240808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GERON CORP
		CENTRAL INDEX KEY:			0000886744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				752287752
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-20859
		FILM NUMBER:		241186008

	BUSINESS ADDRESS:	
		STREET 1:		919 EAST HILLSDALE BOULEVARD
		STREET 2:		SUITE 250
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6504737700

	MAIL ADDRESS:	
		STREET 1:		919 EAST HILLSDALE BOULEVARD
		STREET 2:		SUITE 250
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GERON CORPORATION
		DATE OF NAME CHANGE:	19960521
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>gern-20240808.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-08-07T19:03:38.5905+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:gern="http://www.geron.com/20240808" xmlns:calc="https://xbrl.org/2023/calculation-1.1" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_da688d94-9a71-4034-a76d-30e3fd2cb791" name="dei:EntityCentralIndexKey" contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201">0000886744</ix:nonNumeric><ix:nonNumeric id="F_bebe8c8c-6a52-4ec6-a035-005d5e361a6a" name="dei:AmendmentFlag" contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201" format="ixt:fixed-false">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="gern-20240808.xsd"/></ix:references><ix:resources><xbrli:context id="C_70941392-65ed-4bbc-b71c-749dbbd4f201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-08</xbrli:startDate><xbrli:endDate>2024-08-08</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">___________</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_953f7a44-0237-42fd-9213-d50fb4205c09" contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PURSUANT TO SECTION 13 OR 15(d) OF THE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES EXCHANGE ACT OF 1934</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1fa5fce6-646a-46d4-90d6-f3ceb4a374e1" contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Aug</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ust</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 8, 2024</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4b7c3dfa-ba24-4232-b2cb-611f6958291d" contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:33.333%;"/>
    <td style="width:33.333%;"/>
    <td style="width:33.333%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e0e07057-d6d8-4e0b-8676-788890156f05" contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_801711b3-0653-42d8-9742-f6d5e3a8ee55" contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">000-20859</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_432ad2e6-48d3-414d-82b1-0b54a4f42d8a" contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">75-2287752</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(State or other jurisdiction of incorporation)</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(IRS Employer Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b698a9e1-00a9-42f4-b360-34c35aa56670" contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">919 E. HILLSDALE BLVD</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">., </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a4d756f-9f47-4c26-b844-83ecba9f4761" contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SUITE 250</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1737c455-8ba1-480f-9f1d-f71457241207" contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FOSTER CITY</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_04e014c2-b753-4aed-bd14-39836458ce6e" contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LIFORNIA </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5d66f616-5fe6-480e-bbff-60ef5fcf4a13" contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">94404</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (Address of principal executive offices, including zip code)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5543dd10-4396-4f06-9355-96926b6b669d" contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">650</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_adb2ab3b-4cc8-4094-81a1-755d95c9b1c9" contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">473-7700 </span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Registrant&#8217;s telephone number, including area code)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">N/A</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Former name or former address, if changed since last report)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_e8df41cb-7501-42a8-b75a-6c09c3816800" contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201" name="dei:WrittenCommunications" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_441bba0a-751f-4093-b3f3-7922caff1f4f" contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201" name="dei:SolicitingMaterial" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_eff0741d-b320-4e41-b729-219ae6012b29" contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_b40d7406-a359-4c97-afff-2ab8b33877ee" contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:33.34%;"/>
    <td style="width:22.22%;"/>
    <td style="width:44.44%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.075in;"><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title of each class</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_e2c7e73c-c40d-4b80-8c51-00244fcc77db" contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, $0.001 par value</span></ix:nonNumeric></span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.075in;"><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_eb5b91c0-6ab5-45c9-baea-d465e42592fb" contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">GERN</span></ix:nonNumeric></span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.075in;"><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_814ca984-e7d0-416f-97b7-2c9fc8887333" contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company  </span><span style="font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_12f29013-3ba6-41bf-87d8-46fa5a775828" contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="eolpage2"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:9%;"/>
    <td style="width:91%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 2.02</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">. Results of Operations and Financial Condition</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 8, 2024, Geron Corporation (the "Company") issued a press release announcing its financial results and business highlights for the three and six months ended June 30, 2024. A copy of the press release is attached as Exhibit 99.1.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in Item 2.02 and in the accompanying Exhibit 99.1 to this Current Report shall be deemed to be &#8220;furnished&#8221; and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and shall not be incorporated by reference into any filing made by the Company with the U.S. Securities and Exchange Commission under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d)  Exhibits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1.02%;"/>
    <td style="width:28.574%;"/>
    <td style="width:28.574%;"/>
    <td style="width:33.673%;"/>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit No.</span></p></td>
    <td colspan="3" style="padding-left:0.02in;vertical-align:top;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:7.9pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="border-top:1pt solid #000000;padding-left:0.02in;vertical-align:top;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="border-top:1pt solid #ffffff03;padding-left:0.02in;vertical-align:top;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="border-top:1pt solid #000000;padding-left:0.02in;vertical-align:top;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
    <td colspan="3" style="padding-left:0.02in;vertical-align:top;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gern-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press release dated August 8, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td colspan="3" style="padding-left:0.02in;vertical-align:top;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURE</span></p>
  <p style="margin-left:4.173%;text-indent:-7.477%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6.06%;"/>
    <td style="width:24.24%;"/>
    <td style="width:8.08%;"/>
    <td style="width:7.08%;"/>
    <td style="width:54.54%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;August 8, 2024</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">/s/ Scott A. Samuels</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Scott A. Samuels</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</span></p></td>
    <td style="text-indent:252pt;vertical-align:top;"><p style="text-indent:-252pt;padding-left:252pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Executive Vice President,</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:252pt;vertical-align:top;"><p style="text-indent:-252pt;padding-left:252pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Legal Officer and</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:252pt;vertical-align:top;"><p style="text-indent:-252pt;padding-left:252pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Secretary</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>gern-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.25in;min-height:0.69in;box-sizing:border-box;"><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><img src="img50521483_0.jpg" alt="img50521483_0.jpg" style="width:119px;height:58px;">&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">U.S. commercial launch of RYTELO&#153; (imetelstat) began in June 2024 for patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia who are relapsed/refractory to or ineligible for etythropoiesis-stimulating agents (ESAs), regardless of ring sideroblast (RS) status</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;"><br></font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">NCCN Guidelines</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> updated to include the use of RYTELO in both RS+ and RS- patients for second-line treatment of symptomatic anemia in patients with lower-risk MDS and for first-line treatment of patients who are ESA ineligible (serum EPO &gt;500 mU/mL) </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;"><br></font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">FOSTER CITY, Calif.,</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> August </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">8, 2024 </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">-- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results and business highlights for the second quarter of 2024.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;We are thrilled to have begun the launch of RYTELO, our first commercial product, in June, and are encouraged by the early success we are seeing and the reception from the medical community over these first six weeks ,&#34; said John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer. &#34;Our field teams have mobilized efficiently and have already interacted with approximately 60% of our top decile 1-4 accounts across the community and academic settings. This has contributed to gratifying uptake &#x2013; as of July 31, 2024, we estimate that approximately 160 patients have received RYTELO, which is encouraging given the very early stage of this launch. Further, the MDS NCCN Guidelines, which guide clinical decision-making, prescriber behavior and reimbursement decisions, were updated at the end of July to include RYTELO as a Category 1 and 2A treatment of symptomatic anemia in patients with lower-risk MDS. With the introduction of RYTELO as a new therapeutic option, we are seeing increasing dialogue among hematologists rethinking treatment approaches for eligible patients with lower-risk MDS with transfusion-dependent anemia, regardless of ring sideroblast status, and we believe that RYTELO can become part of the standard-of-care for these patients.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Business Highlights</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Received approval on June 6, 2024 from the U.S. Food &amp; Drug Administration (FDA) of RYTELO for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Launched RYTELO commercially in the U.S., with both dosage strengths available for prescribers to order from specialty distributors as of June 27, 2024.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The National Comprehensive Cancer Network&#174; (NCCN&#174;) updated the MDS NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines&#174;) to include RYTELO for the treatment of symptomatic anemia in patients with LR-MDS. For both RS+ and RS- patients, RYTELO has a Category 1 designation for second-line treatment regardless of first-line treatment and a Category 2A designation for first-line treatment of patients who are ESA ineligible (serum EPO &gt;500 mU/mL). </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Achieved approximately 70% enrollment in the Phase 3 IMpactMF trial of imetelstat as of August 2024, which has a primary endpoint of overall survival, in patients with myelofibrosis (MF) who are relapsed/refractory to JAK-inhibitors. As previously disclosed, based on the most recent planning assumptions for enrollment and death rates in the trial, an interim analysis is expected in early 2026 (when approximately 35% of planned enrolled patients have died) and final analysis is expected in early 2027 (when approximately 50% of planned enrolled patients have died). </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Expanded the dose level 4 cohort (imetelstat 9.4 mg/kg) in the Part 1 dose-finding stage of the Phase 1 IMproveMF study evaluating imetelstat as a combination therapy with ruxolitinib in patients with </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.4in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.25in;min-height:0.69in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">frontline MF. This followed a unanimous decision by the study&#x2019;s Safety Evaluation Team (SET), who in July 2024 reviewed data from the first three patients in the dose level 4 cohort and identified no dose-limiting toxicities.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Second Quarter 2024 Financial Results</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">As of June 30, 2024 the Company had approximately $430.4 million in cash, cash and equivalents and marketable securities.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Net Loss</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">For the three and six months ended June 30, 2024, the Company reported a net loss of $67.4 million, or $0.10 per share, and $122.8 million, or $0.19 per share, respectively, compared to $49.2 million, or $0.09 per share and $87.3 million, or $0.16 per share, respectively, for the three and six months ended June 30, 2023.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Revenues</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Total product revenue, net for the three and six months ended June 30, 2024, was approximately $780,000.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Total net revenues for the three and six months ended June 30, 2024, were $882,000 and $1.2 million, compared to $29,000 and $50,000 for the same periods in 2023. The increase in revenue is due to product revenue from U.S. sales of RYTELO, which was available for prescribers to order from specialty distributors as of June 27, 2024.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Operating Expenses</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Total operating expenses for the three and six months ended June 30, 2024 were $70.2 million and $126.7 million, compared to $52.0 million and $92.1 million for the same periods in 2023.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Cost of goods sold was approximately $17,000 for the three and six months ended June 30, 2024, which consisted of costs to manufacture and distribute RYTELO.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Research and development expenses for the three months and six months ended June 30, 2024 were $30.8 million and $60.2 million, respectively, and $35.5 million and $62.7 million, for the same periods in 2023. The decrease is primarily due to IMerge Phase 3 operations moving into the long-term follow-up stage.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Selling, general and administrative expenses for the three and six months ended June 30, 2024 were $39.4 million, and $66.5 million, respectively, and $16.5 million and $29.4 million for the same periods in 2023. The increase in selling, general and administrative expenses primarily reflects higher commercial launch expenses, increases in headcount and stock-based compensation expense recognized due to the vesting of performance-based stock options upon FDA approval of RYTELO.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Interest income was  $5.3 million and $9.6 million for the three and six months ended June 30, 2024, compared to $4.7 million and $8.6 million for the same periods in 2023. The increase in interest income primarily reflects a larger marketable securities portfolio with the receipt of net cash proceeds from the underwritten offering completed in March 2024, as well as higher yields from recent marketable securities purchases.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Interest expense was $3.3 million and $6.8 million for the three and six months ended June 30, 2024, compared to $2.0 million and $3.9 million for the same periods in 2023. The increase in interest expense primarily reflects rising interest rates. Currently, we have $80.0 million in principal debt outstanding. Interest expense reflects interest owed under the loan agreement, as well as amortization of associated debt issuance costs and debt discounts using the effective interest method and accrual for an end of term charge.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.4in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.25in;min-height:0.69in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">2024 Financial Guidance</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">For fiscal year 2024, we expect total operating expenses to be in the range of approximately $270 million to $280 million, which includes non-cash items such as stock-based compensation expense, amortization of debt discounts and issuance costs, and depreciation and amortization.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Based on our current operating plans and assumptions, we believe that our existing cash, cash equivalents, and marketable securities, together with projected revenues from U.S. sales of RYTELO, will be sufficient to fund our projected operating requirements into the second quarter of 2026.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">As of June 30, 2024, we had 220 full-time employees. We plan to grow to a total of approximately 230-260 employees by year-end 2024.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Conference Call</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Geron will host a conference call at 8:00 a.m. ET on Thursday, August 8, 2024, to discuss business updates and second quarter financial results.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">A live webcast of the conference call and related presentation will be available on the Company&#x2019;s website at www.geron.com/investors/events. An archive of the webcast will be available on the Company&#x2019;s website for 30 days.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Participants may access the webcast by registering online using the following link, </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">https://events.q4inc.com/attendee/182024239</font></font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About RYTELO (imetelstat)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">RYTELO (imetelstat) is an FDA-approved oligonucleotide telomerase inhibitor for the treatment of adult patients with low-to-intermediate-1 risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). It is indicated to be administered as an intravenous infusion over two hours every four weeks.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">RYTELO is a first-in-class treatment that works by inhibiting telomerase enzymatic activity. Telomeres are protective caps at the end of chromosomes that naturally shorten each time a cell divides. In LR-MDS, abnormal bone marrow cells often express the enzyme telomerase, which rebuilds those telomeres, allowing for uncontrolled cell division. Developed and exclusively owned by Geron, RYTELO is the first and only telomerase inhibitor approved by the U.S. Food and Drug Administration.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Geron aims to ensure broad access to RYTELO for eligible patients. Accordingly, our REACH4RYTELO&#153; Patient Support Program provides a range of resources that support access and affordability to eligible patients prescribed RYTELO.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Geron</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO (imetelstat) is FDA-approved for the treatment of adult patients with lower-risk MDS with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">www.geron.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> or follow us on </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">LinkedIn</font></font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About IMpactMF Phase 3</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.4in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.25in;min-height:0.69in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:21pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">IMpactMF is an open label, randomized, controlled Phase 3 clinical trial with registrational intent. The trial is designed to enroll approximately 320 patients with intermediate-2 or high-risk myelofibrosis (MF) who are relapsed after or refractory to prior treatment with a JAK inhibitor, also referred to as relapsed/refractory MF. Patients will be randomized to receive either imetelstat or best available therapy. The primary endpoint is overall survival (OS). Key secondary endpoints include symptom response, spleen response, progression free survival, complete remission, partial remission, clinical improvement, duration of response, safety, pharmacokinetics, and patient reported outcomes. IMpactMF is currently enrolling patients. For further information about IMpactMF, including enrollment criteria, locations and current status, visit ClinicalTrials.gov/NCT04576156.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:21pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About ImproveMF</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:21pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">IMproveMF is a single arm, open label, two-part Phase 1 study to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of imetelstat in combination with ruxolitinib as a frontline treatment in patients with intermediate-2 or high-risk MF (frontline MF). In both parts, patients will receive ruxolitinib followed by imetelstat, a dosing schedule that showed synergistic and additive effects of the two agents in preclinical experiments. Part 1 will enroll up to 20 frontline MF patients who, at the time of enrollment, have received an optimized dose of ruxolitinib, to which imetelstat treatment will be added at increasing dose levels based on safety and tolerability. The primary purpose of Part 1 is to identify a safe dose for treating frontline MF patients with a combination of imetelstat and ruxolitinib. If a safe dose is identified in Part 1, participants in Part 2 will be JAK inhibitor na&iuml;ve and will receive treatment with ruxolitinib after screening and enrollment at a starting dose based on standard-of-care or local prescribing information. Treatment with single-agent ruxolitinib will continue for at least 12 weeks, including four consecutive weeks at a stable dose prior to the addition of imetelstat. Part 2 is designed to confirm the safety profile of imetelstat in combination with ruxolitinib and to evaluate for preliminary clinical activity of the combination.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">IMPORTANT SAFETY INFORMATION ABOUT RYTELO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">WARNINGS AND PRECAUTIONS</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Thrombocytopenia</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">RYTELO can cause thrombocytopenia based on laboratory values. In the clinical trial, new or worsening Grade 3 or 4 decreased platelets occurred in 65% of patients with MDS treated with RYTELO.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Monitor patients with thrombocytopenia for bleeding. Monitor complete blood cell counts prior to initiation of RYTELO, weekly for the first two cycles, prior to each cycle thereafter, and as clinically indicated. Administer platelet transfusions as appropriate. Delay the next cycle and resume at the same or reduced dose, or discontinue as recommended.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Neutropenia</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">RYTELO can cause neutropenia based on laboratory values. In the clinical trial, new or worsening Grade 3 or 4 decreased neutrophils occurred in 72% of patients with MDS treated with RYTELO.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Monitor patients with Grade 3 or 4 neutropenia for infections, including sepsis. Monitor complete blood cell counts prior to initiation of RYTELO, weekly for the first two cycles, prior to each cycle thereafter, and as clinically indicated. Administer growth factors and anti-infective therapies for treatment or prophylaxis as appropriate. Delay the next cycle and resume at the same or reduced dose, or discontinue as recommended.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Infusion-Related Reactions</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">RYTELO can cause infusion-related reactions. In the clinical trial, infusion-related reactions occurred in 8% of patients with MDS treated with RYTELO; Grade 3 or 4 infusion-related reactions occurred in 1.7%, including</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.4in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.25in;min-height:0.69in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">hypertensive crisis (0.8%). The most common infusion-related reaction was headache (4.2%). Infusion-related reactions usually occur during or shortly after the end of the infusion.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Premedicate patients at least 30 minutes prior to infusion with diphenhydramine and hydrocortisone as recommended and monitor patients for one hour following the infusion as recommended. Manage symptoms of infusion-related reactions with supportive care and infusion interruptions, decrease infusion rate, or permanently discontinue as recommended.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Embryo-Fetal Toxicity</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">RYTELO can cause embryo-fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with RYTELO and for 1 week after the last dose.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ADVERSE REACTIONS</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Serious adverse reactions occurred in 32% of patients who received RYTELO. Serious adverse reactions in &gt;2% of patients included sepsis (4.2%) and fracture (3.4%), cardiac failure (2.5%), and hemorrhage (2.5%). Fatal adverse reactions occurred in 0.8% of patients who received RYTELO, including sepsis (0.8%).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Most common adverse reactions (&#x2265;10% with a difference between arms of &gt;5% compared to placebo), including laboratory abnormalities, were decreased platelets, decreased white blood cells, decreased neutrophils, increased AST, increased alkaline phosphatase, increased ALT, fatigue, prolonged partial thromboplastin time, arthralgia/myalgia, COVID-19 infections, and headache.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Please see RYTELO (imetelstat) full Prescribing Information, including Medication Guide, available at https://pi.geron.com/products/US/pi/rytelo_pi.pdf.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Use of Forward-Looking Statements</font><font style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the &#x201c;safe harbor&#x201d; provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such statements, include, without limitation, those regarding: (i) the Company&#x2019;s views, estimates and expectations concerning the commercial launch of RYTELO, including estimates of accounts reached and patients receiving RYTELO; (ii) the potential impact on clinical decision-making, prescriber behavior and reimbursement decisions of the inclusion of RYTELO in the NCCN Guidelines as a Category 1 and 2A treatment of symptomatic anemia in patients with lower-risk MDS; (iii) the Company seeing increasing dialogue among hematologists rethinking treatment approaches for eligible patients with lower-risk MDS with transfusion-dependent anemia, regardless of ring sideroblast status, and the Company&#x2019;s belief that RYTELO can become part of the standard-of-care for these patients; (iv) that the interim analysis of IMpactMF is expected in early 2026 and the final analysis is expected in early 2027; (v) the Company&#x2019;s projections and expectations regarding the sufficiency of its cash resources and expected available resources to fund its projected operating requirements into Q2 2026, and the assumptions underlying such projections and expectations; (vi) the Company&#x2019;s projections for total operating expenses for fiscal 2024 and employee headcount as of the end of 2024; (vii) that inhibiting telomerase activity aims to potentially reduce proliferation and induce death of malignant cells; (viii) that Geron aims to ensure broad access to RYTELO; (ix) that IMpactMF has registrational intent; and (x) other statements that are not historical facts, constitute forward-looking statements. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. These risks and uncertainties, include, without limitation, risks and uncertainties related to: (a) whether Geron is successful in commercializing RYTELO (imetelstat) for the treatment of patients with LR-MDS with transfusion dependent anemia; (b) whether Geron overcomes potential delays and other adverse impacts caused by enrollment, clinical, safety, efficacy, technical, scientific, intellectual property, manufacturing and regulatory challenges in order to have the financial resources for and meet expected timelines and planned milestones; (c) whether regulatory authorities permit the further development of imetelstat on a timely basis, or at all, without any clinical holds; (d) whether any future safety or efficacy results of imetelstat treatment cause the benefit-risk</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.4in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.25in;min-height:0.69in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">profile of imetelstat to become unacceptable; (e) whether imetelstat actually demonstrates disease-modifying activity in patients and the ability to target the malignant stem and progenitor cells of the underlying disease; (f) that Geron may seek to raise substantial additional capital in order to continue the development and commercialization of imetelstat; (g) whether Geron meets its post-marketing requirements and commitments in the U.S. for RYTELO for the treatment of patients with LR-MDS with transfusion dependent anemia; (h) whether there are failures or delays in manufacturing or supplying sufficient quantities of imetelstat or other clinical trial materials that impact commercialization of RYTELO for the treatment of patients with LR-MDS with transfusion dependent anemia or the continuation of the IMpactMF trial; (i) that the projected timing for the interim and final analyses of the IMpactMF trial may vary depending on actual enrollment and death rates in the trial; and (j) whether the EMA will approve RYTELO for the treatment of patients with LR-MDS with transfusion dependent anemia and whether the FDA and EMA will approve imetelstat for other indications on the timelines expected, or at all. Additional information on the above risks and uncertainties and additional risks, uncertainties and factors that could cause actual results to differ materially from those in the forward-looking statements are contained in Geron&#x2019;s filings and periodic reports filed with the Securities and Exchange Commission under the heading &#x201c;Risk Factors&#x201d; and elsewhere in such filings and reports, including Geron&#x2019;s quarterly report on Form 10-Q for the quarter ended March 31, 2024, and subsequent filings and reports by Geron. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, and the facts and assumptions underlying the forward-looking statements may change. Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events, or circumstances.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Financial table follows.<br></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.4in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.63in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">GERON CORPORATION</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.531%;"></td>
    <td style="width:1.76%;"></td>
    <td style="width:11.858%;"></td>
    <td style="width:1.76%;"></td>
    <td style="width:11.858%;"></td>
    <td style="width:1.76%;"></td>
    <td style="width:11.858%;"></td>
    <td style="width:1.76%;"></td>
    <td style="width:11.858%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td colspan="4" style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td colspan="4" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">Three Months Ended</font></p></td>
    <td colspan="4" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">Six Months Ended</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td colspan="4" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">June 30,</font></p></td>
    <td colspan="4" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">June 30,</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">(In thousands, except share and per share data)</font></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">2024</font></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">2023</font></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">2024</font></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">2023</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">(Unaudited)</font></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">(Unaudited)</font></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">(Unaudited)</font></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">(Unaudited)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Revenues:</font></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;&#160;Product revenue, net</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">780</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">-</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">780</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">-</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;&#160;Royalties</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">102</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">29</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">406</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">50</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">882</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">29</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">1,186</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">50</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Operating expenses:</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;&#160;Cost of goods sold</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">17</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">-</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">17</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">-</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;&#160;Research and development</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">30,779</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">35,490</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">60,152</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">62,709</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;&#160;Selling, general and administrative</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">39,419</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">16,490</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">66,484</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">29,384</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Total operating expenses</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">70,215</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">51,980</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">126,653</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">92,093</font></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Loss from Operations</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(69,333)</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(51,951)</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(125,467)</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(92,043)</font></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Interest income</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">5,332</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">4,738</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">9,571</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">8,591</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Interest expense</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(3,319)</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(2,003)</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(6,752)</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(3,925)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Other income and (expense), net</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(63)</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(11)</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(125)</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">28</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Net loss</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(67,383)</font></p></td>
    <td style="vertical-align:middle;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(49,227)</font></p></td>
    <td style="vertical-align:middle;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(122,773)</font></p></td>
    <td style="vertical-align:middle;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(87,349)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">Basic and diluted net loss per share:</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;&#160;Net loss per share</font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(0.10)</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(0.09)</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(0.19)</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(0.16)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;&#160;Shares used in computing net loss per share</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">653,904,978</font></p></td>
    <td style="vertical-align:middle;border-bottom:2.25pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">547,280,946</font></p></td>
    <td style="vertical-align:middle;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">628,699,214</font></p></td>
    <td style="vertical-align:middle;border-bottom:2.25pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">553,772,809</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.093%;"></td>
    <td style="width:1.499%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.954%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.499%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.954%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">June 30,</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">December 31,</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">(In thousands)</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">2024</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">2023</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">(Unaudited)</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">(Note 1)</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Current assets:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Cash, cash equivalents and restricted cash</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">118,068</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">71,138</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;Current marketable securities</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">245,789</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">263,676</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Other current assets</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">9,451</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">6,534</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">373,308</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">341,348</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Noncurrent marketable securities</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">66,505</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">43,298</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Property and equipment, net</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">1,626</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">1,177</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Deposits and other assets</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">7,960</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">8,253</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">449,399</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">394,076</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Current liabilities</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">103,540</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">108,070</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Noncurrent liabilities</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">39,164</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">38,057</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Stockholders&#x2019; equity</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">306,695</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">247,949</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">449,399</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">394,076</font></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Note 1: 	Derived from audited financial statements included in the Company&#x2019;s annual report on Form 10-K for the year ended December 31, 2023.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.11in;min-height:0.2in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.63in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">CONTACT:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Aron Feingold</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Vice President, Investor Relations and Corporate Communications</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Kristen Kelleher</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Associate Director, Investor Relations and Corporate Communications</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">investor@geron.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">media@geron.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">###</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.11in;min-height:0.2in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img50521483_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img50521483_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -V!PX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBCM0!D:OK(TR6WB6+S99FP%SC ]?UK6]*X3[1_:_C*(]427">F
M$R?UQFN[Q7G8'$RQ$ZDOLIV1TXBDJ2BNMKL6BBBO1.8**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@!*S-=O?L.DSR@X<C:GU/'_UZTZXSQI=
M[IH+-3PH,C#WZ#^M<&98CV&&E);G1A*?M*L8E7P?%YFLM(>B1DCZD@5WM<AX
M)C_X_)?]U1^N:Z^N?)(<N$3[W-,?*]=KL+1117KG&%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 G;->7ZM=?;-5N+@'*LQ"_0<#]!7H6L77
MV/2;F;."J$*?<\#]37F%?+\15_AI+U/7RNG\4SN/!:8TN9_[TQ_D*Z6L'PBN
MW04/]YV/Z_\ UJWJ]K+8\N%@O(X,4[UI>HM%%%=QSA1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 <QXSN-FGPVX/,CY/T _Q(KB*Z'QC<>9J
ML<0/$48S]2?_ -5<]7P><5O:8N7EH?1X"'+07F>B>%@!X=MSZES_ ./&MFL?
MPO\ \BY:_P# _P#T,UL5]E@?]VI^B_(\&O\ Q9>K US?B'6_[.US0+)7VF\N
MB&'JH4KC\W7\JZ3%>*_$35_+^(=M(IXTX1' _O [\_J*]+"TO:SY?)G!BZWL
MJ:?FCVNBFJ0R@@Y!Y!%.KG.I!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *Y?QK_R#[?\ Z[?T-=17+^-?^0?;_P#7;^AKS\T_W.?H=.#_ (\3
MB:***_/CZ4 2"".".0:]6LYQ<VD,XZ2(K?F*\IKT#PI<^?HJ(3EHF*'^?\C7
MT7#U7EK2IOJCR\TA>"GV-VO!_B?:?9O&UQ+C N8DE'Y;?YK7O%>5?&.PXTS4
M57H6@<_7!7_V:OO<NGRUTNY\KF4.:@WV/*J***^B/FSW_P  Z^->\-0F1LW5
MMB&;/4D#AOQ'ZYKJZ\ \ >(?[!\1QB5\6EUB&7/09/RM^!_0FO?\U\UC:'LJ
MKMLSZ? U_:TE?="T445R':%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %)15&[UG3=/_X_-0M8#Z2RJI_4TTFW9$N2
M2NV7Z*Y:X^(?A:V;#:JCGTCC=_U JC+\5/#29VR73X_NP]?SK18>J]HLR>)H
MK>2^\[>BN#'Q8\.D@%+T>YA'^-6HOB?X6D^_>RQ?[\#G^0-4\-67V6)8N@_M
M([&BL*V\9^'+H@1ZS:9/0/($/_CV*V8;B&XC$D,J2(>C(P(K*4)1^)&L:D)?
M"[DM%%%26%%%% "=Z**X7X@>,QH-F;"Q<?VC.OWA_P L5_O'W]/SJZ=.522C
M$RJU8TH<TB]>>/\ 1K'Q'_8\TN"!AY\C8C_W2?\ .*ZI6#@,K9!Y!'>OEAF9
MR68L6)R2>237;>#/B#<Z"T=E?EY].Z+W:'_=]1[?E7IU\NM!.GOU/+H9G>=J
MFW0]SHJO9WMMJ%K'=6DR2PR#*NAR"*L5Y+33LSV$TU="T444#"BBB@ HHHH
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M)XET*0X36=/8^@N4/]:OP75O<KF&>*4>J.&_E2<9+= IQ>S)Z*,T4BPHHHH
M**** "BBB@ HHHH **** "BBB@ I*,@=Q5"YUG3+3_CYU&TAQU\R95_F::3>
MQ+DENR_16$_C/PY'G=K5D<''RS!OY4S_ (3GPS_T&;;_ +ZJO93_ )61[>G_
M #+[SH**QH_%?A^4X76K#/H;A!_6M*"\MKI=UO<12KZHX8?I2<)+=%*I&6S+
M%%&:*DL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHS0 E%0SW=O;+NFGBB'J[A?YU0?Q+H49P^LZ>I]#<H/ZTU&3V1#G
M%;LU:*R/^$I\/_\ 0<T[_P "H_\ &K46K:;.<1:A:R'T693_ %IN$ET!3@]F
M7J*0,I&0>*6I+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI1=IH]BAB:=97BRU1116!TA1110 4444 %%%% !1110 4444 %%%% !1110
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M(^*[?Q1IOFJ!'=18$\.?NGU'L>U='7STX2A+EDCZ.$XSCS1>@M%%%26%%%%
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M?2/A[Q%8>(]/%U929Q@21M]Z-O0BMC%?-GA[Q#=^'-42]M6ROW98CTE7/3_
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MA:16MM&L<$2A41>@ JQ117SC=]6?2I)*R%HHHH&%%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?@ZU9UQ+=9N'_P"!?=_\= KK:^9QE7VE9OHCZC TO9T4NKU%HHHKE.P****
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MYN9QO13[,]+*I6K-=T>A4445X)]$%%%% !1110 4444 %%%% !1110 4444
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M_P#V='_"F#_T'O\ R3_^SKU:BCZ_B/YOP0?V?A_Y?Q9Y3_PI@_\ 0>_\D_\
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M 4444 %%%% !114<DB0Q-)(P5%!9F/  [F@#ROXPZH"^GZ4K?=S<2#_QU?\
MV:O+*UO$NKMKOB&\U#YO+DDQ$#V0<+^@K*KZ?"TO9THQ9\GBZOM:LI(2BE/6
MMOP?IAU?Q7I]J1F/S1))Z;5^8_GC%;3DHQ<GT,:<'.2BNI[WH%@=,T#3[(C#
M0P(KCWQS^M:= H%?)R;;;9]A%**44+1112*$KG_'/_(DZM_UP-=!7/\ CG_D
M2=6_ZX&M*/\ $CZHRK?PY>C/G6BBBOK#Y .QKW3X5_\ (EQ_]=W_ )UX7V->
MZ?"O_D2X_P#KN_\ .O.S/^"O4]'*OX_R.WHHHKP#Z,**** "BBB@ HHHH **
M** "BBB@ HHHH 2JFJ_\@F\_ZX/_ .@FK=5-5_Y!-Y_UP?\ ]!-./Q(F?PL^
M8****^N6Q\:]PKU3X,?>UOZ0?^U*\KKU3X,?>UOZ0?\ M2N/,/\ =W\OS.S+
MO]XC\_R/5Z***^</J HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAT;2;73X/]7!&$!]3W)^IYKS,RK\L%377\CT\LH<]3G>R-"BBBO"/H0HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 5RWB3XH:?IRM;Z3MOKKIO'^J4_7^+\./>O(M3U6^UB^:[O[AYIF[GH!Z =
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M_M5OK&:W;I(I /H>QKBIRY9)G1B*?M*;B>6T4Z5&BD:-QAT)5AZ$=:;7IGS
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MRV/I,-AH4(V6XM%%%<YTA1110 4444 ?/WQ'_P"1^U3ZQ?\ HI:Y6NJ^(_\
MR/VI_6+_ -%+7*U]3AOX,/1'R.)_C3]6%=?\,O\ D>K+_<D_] -<A77_  R_
MY'JR_P!R3_T T8G^#+T8\+_&AZH]\HHHKY8^M"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@!.U<QXP\(V_B?3\?+%>Q#,,VW_ ,=/L?TKIZ*J$Y0DI19%
M2$:D7&6Q\P:CIUWI5]+9WL!BN(S@J?T(/0@^M5*^B_$_A2P\3V7E7*[+A!^Y
MN%'S(?ZCVKPWQ#X9U/PW=^3>P_NF/[N=>4<?7U]CS7T&%QD*RL]&?.8O!3H.
MZUB8U%%%=QPB@XY'6NIT;X@^(-'"H+K[7 /^6=SE\#_>^]^N*Y6BHG2A45IJ
MY<*LZ;O%V/8=/^+VGR@+J%A/;MZQ$2+_ $(_6NEM/'GAB\QLU:%#Z39C_P#0
M@*^>:*X:F647\-T=T,TK1^*S/IJ/7-)F&8M3LW'7*SJ?Y&I?[5T__G^MO^_J
M_P"-?,%%8_V4OYC?^UW_ "GTK-XDT.WXFUBQ0CL;A<_SK'O?B3X8LP<7YG8?
MPP1LWZXQ^M>!454<KIKXI,B6;5'\*1ZIJ?Q@."FE:9@_PR7+?^RK_C7!ZSXH
MUG72?[0OI'BSD1+\J#_@(Z_C6/17;2PE&GK&)QU<76JZ284445T',%%%=IX1
M^'U[X@=+N]5[33NH)&'D'^R/3W/ZUE5JPI1YILTI49U9<L3+\*^$[WQ1>^7"
M&CM(R/.N".%'H/4^U>^Z9IEII%A%8V42Q0QC 4=_<^I]Z73M.M-*LH[.Q@2&
M&,8"+_GD^]7*^>Q6+E7EY'TF$PD:$?,6BBBN4[ HHHH **** $KG_'/_ ").
MK?\ 7 UT%<_XY_Y$G5?^N!K2C_$CZHRK?PY>C/G6BBBOK#Y .QKW3X5_\B7'
M_P!=W_G7A?8U[I\*_P#D2X_^N[_SKSLS_@KU/1RK^/\ ([>BBBO /HPHHHH
M**** "BBB@ HHHH **** "BBB@!*J:K_ ,@F\_ZX/_Z":MU4U7_D$WG_ %P?
M_P!!-./Q(F?PL^8****^N6Q\:]PKU3X,?>UOZ0?^U*\KKU3X,?>UOZ0?^U*X
M\P_W=_+\SLR[_>(_/\CU>BBBOG#Z@**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^'WOTKF;BTN;.3R[F"6!_P"[*A4_D:[X583^%W//G1J0^)6(J***U,PHHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1=)MM/MQ\D*;<GJQ[D_4\UHT45XC;;NSWHI122%HHHI%!1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"8?V,-=WN+1117,=84444 %%%% !1110 4444 )7F'QBM"]EI=Z!Q'*\1/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJHJJJX4< #M3Z^[P6"AA::C'?JSYS$5Y5I\TA:***[3 **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU@BAB'18T"@?@*GHHS7->^YU)6T0M%%% PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *BEC6:%XVSM<%3C@X-244FDU9@0P6\5M&(H8U
M1%Z*HP*FHHH225D#;;NQ:***8!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
'%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>gern-20240808.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-08-07T19:03:38.8615+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.geron.com/20240808" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:gern="http://www.geron.com/20240808" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.geron.com/20240808/taxonomy/role/Cover" id="Cover">
        <link:definition>100000 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.geron.com/20240808/taxonomy/role/Cover" xlink:href="gern-20240808.xsd#Cover" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CIK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.geron.com/20240808/taxonomy/role/Cover" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140672163957408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 08, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  08,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">000-20859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GERON CORPORATION<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000886744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">75-2287752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">919 E. HILLSDALE BLVD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">SUITE 250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">FOSTER CITY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">473-7700 <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GERN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MM]ON-+&E[!58O4NP5NR%3$)@$QL1L-S*SR\HKMAI75/:[71:%,'SW-(ZW4L
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MP %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ 0SD(69>*NQS     $P(
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M_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%     @ 0SD(620>FZ*M    ^ $
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50
MJ4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*
M9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI
M?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI
M5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( $,Y"%EED'F2&0$
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M;W!S+V%P<"YX;6Q02P$"% ,4    " !#.0A9;REVD>T    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !#.0A9
MF5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( $,Y"%FA_,*Y;@0  #01   8              "
M@0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !#.0A9
MGZ ;\+$"  #B#   #0              @ &P#   >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( $,Y"%F7BKL<P    !,"   +              "  8P/  !?
M<F5L<R\N<F5L<U!+ 0(4 Q0    ( $,Y"%FJQ"(6,P$  "("   /
M      "  740  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !#.0A9)!Z;
MHJT   #X 0  &@              @ '5$0  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " !#.0A999!YDAD!  #/ P  $P
M    @ &Z$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   $
%%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="gern-20240808.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20240808/taxonomy/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="gern-20240808.htm">gern-20240808.htm</File>
    <File>gern-20240808.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "gern-20240808.htm": {
   "nsprefix": "gern",
   "nsuri": "http://www.geron.com/20240808",
   "dts": {
    "inline": {
     "local": [
      "gern-20240808.htm"
     ]
    },
    "schema": {
     "local": [
      "gern-20240808.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://www.geron.com/20240808/taxonomy/role/Cover",
     "longName": "100000 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_70941392-65ed-4bbc-b71c-749dbbd4f201",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20240808.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_70941392-65ed-4bbc-b71c-749dbbd4f201",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20240808.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.geron.com/20240808/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.geron.com/20240808/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.geron.com/20240808/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.geron.com/20240808/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.geron.com/20240808/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.geron.com/20240808/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.geron.com/20240808/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.geron.com/20240808/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.geron.com/20240808/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.geron.com/20240808/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.geron.com/20240808/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "CIK",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.geron.com/20240808/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.geron.com/20240808/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.geron.com/20240808/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.geron.com/20240808/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.geron.com/20240808/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.geron.com/20240808/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.geron.com/20240808/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.geron.com/20240808/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.geron.com/20240808/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.geron.com/20240808/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.geron.com/20240808/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.geron.com/20240808/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.geron.com/20240808/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-24-093307-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-093307-xbrl.zip
M4$L#!!0    ( $,Y"%GAD1W]=A0  *;#   1    9V5R;BTR,#(T,#@P."YH
M=&WM/6MSXDB2W_=7U'INMNTXE]#[@=V]P6#<PXW;[@!Z=^Z^3)14)="TD!A)
MV+"__K)*$@8;\ -H8UONB+:E>N:S,K.R2J?_G Q#=,V2-(BCCQ\42?Z 6.3%
M-(CZ'S\TNLUV^\,_/_WM].\8H[/S]B6Z9#>HX67!-3L+4B^,TW'"T&'WRQ%J
M1V$0,?3[+YT+=!9[XR&+,H31(,M&]5KMYN9&HGX0I7$XSF"L5/+B80UA7'3>
M3!CA[]$9R1BJJ[*J8]G&LM53G+JLU35;,AS9^&]9KLOR7+-X-$V"_B!#A]X1
MXJU@["AB83A%YT%$(B\@(>J6@Q[#+#T)-<(0=7BK%'58RI)K1J6\ST$&Z "4
M1.G'@[F9WVA2G/1KBN,XM0FO<Y!7JD_<)*3!K"Y_%#55639K>>%"U6QI52.O
MFLU7#18F,%];JP$:,P"-E?4!\=_75.?%+DEGU2?WZB_ QTO+JL%D5;\*GP:G
M."=X63V*HTL@?!)XRYO1+*EETQ&K044<Y35GLTJ#97,"")3:[U\NNMZ #0F^
M"SIE=["?,D_JQ]<U*("VJC:#)(UU5;'6836O43;HLR1:J TOXDBP+><SV9;M
MLJI'P@+@=)&RJE;C9>-0\#96).46L1F&J2X,4$[]%J^U+"%1ZL?)4'3 T6YP
ML=#F^UD.TKI.5!7+*E;,LI-QEJS$BU.#TH-/?T.G T8H_$:G69"%[).-?SNM
MY7_RET.6$2'LF/TU#JX_'C3C* ,5@'M [P/DY4\?#S(VR6I"A&J\TUK1ZZD;
MTRE*LVG(/AX,2=(/HCHBXRS^>S <Q0G0/#L9$<KU4AW9H\G)@1B5!M=E(QJD
MHY!,.0\R*#T-)G7>-TOR/P-*623^O&52%-"/!^=_4&+:-G5T[!!+P;JLZ9A8
M)L6:S#2?JIYK.8#OB SY*"RHMR( >]H$<!(2MB/*)K^Q:0'B).LP'X#_PY(=
M7=$<%9L&HUAW70^[EN)A2W>HZU+=!UH>?)+AQ[9-2]=/:PM36SY3E[G,]FP/
MF\10L<X\$Q-9 Y:0#6HPS52(2>9GV@ E3+DB/@])_UDS1#G??#P 1JO[P01J
M^B0$7?))_+HWZ]HBKA/FLP06%)9^.N5ZI9X*,889(*%GZEP;?#Q(@<@AEVGQ
M;I#P"7+YPZ6D29.4 L.([N?[%(]I/$[$D]";]0)*@;+'TJ%HR@1ERZ> \F<_
M8 D2TV9+I;79_FV1CG<;?RI?+?8^ H3%M'P"K99D?.W[-%OZ[++=;=ELFG1%
MU;*D?"X'J2V@IL3C#'&U.6&I@4S=E:UA$.$!XRMF70DB+EVS6J.RC@]]XS3X
M#ZLK\B@[R6489_&H+I^(,I\,@W!:[P5#E@H[HA,/2516=.,LBX=0ET\0DS#H
M1_60^1D?+!V1J!SF9A!D#,,;C]5'"<,W"1F=W!E[[7 PUDU LP%P<X8+M02#
M_.,GQ91/3FM\+ !OM'/@/!B7)7?!\^(P3NH_R>+G9#6P-SDUW#BDVX#^VV6[
MUSI#W5ZCU^J^5R1T6\UOG7:OW>JBQN49:OW>_+5Q^;F%FE=?OK2[W?;5Y7O%
MS+\;W5_;EY][5Y?'Z$QJ2F!I&[KS7K'QQ^W/BZ.@4H>[H/#Y5><+*H&?G\\3
M^CY8;L(YAN9;1(=U6]4LK*L^Q8ZJ:)@:LN_J(%>>[#S/4KLU^TKW6YC>>X%0
MX2P4O'378JPDZ U*$*RDG=9E#W5:7Z\ZO66B]$(30^^5(E^_=;K?&D"2WA4"
M2Z<'Y@Q2-'3508IQ2(_0U3GJ_=JJ*/7R@,_9H3,;M-'L<0HICJ:_.%HJC;D%
M8$6<._91A_'P%CHLGQD!1YVE&6+7/(">B&)&C^I+[9&7%LWMVD:*3PS?8R8V
M=9-@W:0Z=F1J8E_SF*L3S=*9LBW;Z*N(C+3R>,EBF(O"&SR$40:\&:9DBJ=
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M+E'SJO/UJM/HM:\NWY,)LH_YHJ8DF^NR+G5)79=T:4NRO:;86E]LZ)+Q@VZ
M?#4'2%=N 0*IZP_E4KQZ*'.Y61[EW-(0Z'4@<0>9-OL!V :D^V7Z=B3@Z?L!
MM;2&NA[, #4DU"7#,0N77J/Z#O3HFQ6."K#7!MB&5[Z^'86V,E)1J:PW+0 5
M8*\-L$UO<G]09\W'UU2#7\GY . +D<F\Q4)@,G^U_^AIS3X6_J_ 8_Q+'FG
M@3JNE-[;$J$*L JP]ZOFFH. ^>B"]4F(KGP?5!W_%NF/_S+!F^6L"K *L#T!
M[-TJN2[S$I:19%KEF%7 5< ]X;M^#X%W-T'P0Q/Z<I/@D5=COS<"5IEK+Y:Y
MIFV>N79:<V,Z_?2WT]H@&X:?_A]02P,$%     @ 0SD(65!P_[LL"0  ^&P
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MH;G0MA^W/\ ??UTS/*)SZ&I._"H=!T&$V1U'P*ZFTR=*8K3#SE:WF-5 _T2
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MMJX(\#ET,#?6[7Q[IH H7Z^4Q<^>KY]:"B9UO&72_V#=B/N;7C*2;<U@>\\
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M#]!RA'GB/7X?Y:^UXS_J9W7AQ6$H$SK^P,TB;R+BD3C][_.CSR< D6Y[7^S
MEE(9Z-1-WXFA'+N14)'X/8NDP9]1G(@IH!D,JL6E2B<BB"^!F29*?Q/A3 ;
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M/,C&&2@OW\.*'V)=NXY1&)]81-1JXKJ!M'/L:M_]<T_\=G1Z#'JA6U&,@2F
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M@'KHSP R0,U@YL)SI%>Z4P#:E0+E4\+CO<9;!#("%Q!+^-)3H"PV:QWA>@!
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MBY5\R?=D&00I.R7;D-%_9K:B+@:.J'16%^?F:S3_$@RKB5,;5(+]S!;:F7A
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M-=80529-*J;@@;(AG0>Z)"(37ED8E7.9%ISKOI66@WFH.>5QY&,@&LJ0Y!+
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MD(O/LO:*1![D>O!;*KU)_B7UL53PC4/8& 32'"Y&S (LX6G0&+,1^1#S%'C
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MFPE][_W;_"G!,F#6Z)<WG3<K0 0[7[:7+1'4:RA1KWO;3&YW(K?'IBX+D:W
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MC#9K]O5H.,TN1ZTPVJR)-BVGWU@JI%CI?$2E\TP&V!7-$6,9R82Z#F*S.QC
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M?"P@C,^GM^M%_-QSLS3.N0<N""P@W $^7@O<69RE,/R5]/?-5,U&H]YXF[\
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M2P$"% ,4    " !#.0A9X9$=_784  "FPP  $0              @ $
M9V5R;BTR,#(T,#@P."YH=&U02P$"% ,4    " !#.0A94'#_NRP)  #X;
M$0              @ &E%   9V5R;BTR,#(T,#@P."YX<V102P$"% ,4
M" !#.0A9AC@MGU<O   XH0( #P              @ $ '@  9V5R;BUE>#DY
<7S$N:'1M4$L%!@     #  , NP   (1-      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>gern-20240808_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="gern-20240808.xsd" xlink:type="simple"/>
    <context id="C_70941392-65ed-4bbc-b71c-749dbbd4f201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <startDate>2024-08-08</startDate>
            <endDate>2024-08-08</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201"
      id="F_da688d94-9a71-4034-a76d-30e3fd2cb791">0000886744</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201"
      id="F_bebe8c8c-6a52-4ec6-a035-005d5e361a6a">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201"
      id="F_953f7a44-0237-42fd-9213-d50fb4205c09">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201"
      id="F_1fa5fce6-646a-46d4-90d6-f3ceb4a374e1">2024-08-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201"
      id="F_4b7c3dfa-ba24-4232-b2cb-611f6958291d">GERON CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201"
      id="F_e0e07057-d6d8-4e0b-8676-788890156f05">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201"
      id="F_801711b3-0653-42d8-9742-f6d5e3a8ee55">000-20859</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201"
      id="F_432ad2e6-48d3-414d-82b1-0b54a4f42d8a">75-2287752</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201"
      id="F_b698a9e1-00a9-42f4-b360-34c35aa56670">919 E. HILLSDALE BLVD</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201"
      id="F_4a4d756f-9f47-4c26-b844-83ecba9f4761">SUITE 250</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201"
      id="F_1737c455-8ba1-480f-9f1d-f71457241207">FOSTER CITY</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201"
      id="F_04e014c2-b753-4aed-bd14-39836458ce6e">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201"
      id="F_5d66f616-5fe6-480e-bbff-60ef5fcf4a13">94404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201"
      id="F_5543dd10-4396-4f06-9355-96926b6b669d">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201"
      id="F_adb2ab3b-4cc8-4094-81a1-755d95c9b1c9">473-7700 </dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201"
      id="F_e8df41cb-7501-42a8-b75a-6c09c3816800">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201"
      id="F_441bba0a-751f-4093-b3f3-7922caff1f4f">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201"
      id="F_eff0741d-b320-4e41-b729-219ae6012b29">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201"
      id="F_b40d7406-a359-4c97-afff-2ab8b33877ee">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201"
      id="F_e2c7e73c-c40d-4b80-8c51-00244fcc77db">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201"
      id="F_eb5b91c0-6ab5-45c9-baea-d465e42592fb">GERN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201"
      id="F_814ca984-e7d0-416f-97b7-2c9fc8887333">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_70941392-65ed-4bbc-b71c-749dbbd4f201"
      id="F_12f29013-3ba6-41bf-87d8-46fa5a775828">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
